The clinical testing of an arsphenamine in the treatment of syphilis can hardly reach finality at the hands of a single observer, nor can the validity of conclusions be established short of years of observation. This should be borne in mind as we briefly recite a two years' experience with a new arsphenamine synthetic, bismuth arsphenamine sulphonate, submitted to us in July, 1925, for clinical testing by its originator, Prof. George W. Raiziss. We take this occasion, too, to say that comparisons made by different observers are discussable intelligently only if the modes of administration of a new drug and the technic of its employment in the disease in different clinics bear some resemblance to one another—a detail too often forgotten in clinical as well as in scientific study, and notably illustrated by reported experience with sodium cacodylate and, more recently, sulpharsphenamine. Manufacturers' products will differ in spite of standard
STOKES JH, CHAMBERS SO. BISMUTH ARSPHENAMINE SULPHONATE: CLINICAL OBSERVATIONS ON A NEW ARSPHENAMINE SYNTHETIC IN THE TREATMENT OF SYPHILIS. JAMA. 1927;89(18):1500–1505. doi:10.1001/jama.1927.02690180032009
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: